Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC augmentation in treatment-resistant OCD
NCT06956157Phase 4Active, not recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of acetylcysteine in obsessive compulsive disorder (OCD), sponsored by Guangdong Provincial People's Hospital. Started Jun 2022; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT06956157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956157.